# Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

> **NCT02145910** · PHASE1 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University**

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma
- Tumors Metastatic to Brain

## Interventions

- **DRUG:** Vemurafenib
- **RADIATION:** Whole-brain radiation therapy (WBRT)
- **RADIATION:** Radiosurgery (SRS)

## Key facts

- **NCT ID:** NCT02145910
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2019-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never opened to accrual. There is no clinical benefit to patients.
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145910, "Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02145910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*